We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/4/2019 12:13 | The first Phase II cohort's other investigator, Pravin Dugel MD, Managing Partner, Retinal Consultants of Arizona, Phoenix, Arizona, and Clinical Professor, Roski Eye Institute, USC Keck School of Medicine, Los Angeles, California, said: "When I heard about the rapidity and magnitude of the visual gain in the first patient that Jason treated in this cohort, I was hopeful, but sceptical. Now that I saw this repeated in my first two patients, I am very excited indeed." | someuwin | |
01/4/2019 12:02 | I'm still adding here. | someuwin | |
01/4/2019 11:59 | Thanks rayrac. Have taken some more profits as a precaution. Happy days. | top tips | |
01/4/2019 11:35 | Good luck tt! I don’t know what you will say when it gets to £6.;) | rayrac | |
01/4/2019 11:31 | Up £22k now. :-) | top tips | |
01/4/2019 11:28 | Up £19.5k this morning already. Happy days. | top tips | |
01/4/2019 11:20 | Any idea where my broker buys/sells my shares. I offloaded 50k shares in hur a while ago, and bought 20k here. Not a sign of either trade. Still holding 100k in hur. | rayrac | |
01/4/2019 10:46 | I think the potential of the opportunity here is starting to be realised by the market. I was researching at the weekend and listening to the audio interviews with the retinal specialists found on their website. There is potential to treat any disease involving photoreceptor loss. That includes Macular degeneration ($10 billion market), Diabetic Retinopothy ($10 billion market) plus others. RP is potentially just scratching the surface of opportunity. However, I agree with Rayrac the company will probably get taken out long before the potential is realised. There are risks which we won't know until we have more data but still a good risk/reward IMHO at this level. | pdt | |
01/4/2019 10:30 | Easily achievable I would have thought. But someone will take it away from us.:( I’ve just added a lot more. :) joint top trade of the day...according to the advfn trades. Not showing yet! | rayrac | |
01/4/2019 10:24 | Stifel target 625p N+1 Singer target 900p Edison target 608p | someuwin | |
01/4/2019 09:10 | So am I. Still holding 100k shares. | top tips | |
01/4/2019 09:06 | Woodford doing well out of this! But he needs it. | rayrac | |
01/4/2019 08:43 | Up we go again. | top tips | |
01/4/2019 08:36 | Positive start to the week. | someuwin | |
30/3/2019 10:41 | Doubled my holding. | rayrac | |
29/3/2019 16:24 | Understood | volsung | |
29/3/2019 16:23 | It's old but it was appropriate a couple of US Presidents ago. | dickbush | |
29/3/2019 15:19 | "another couple of quid a share" this year - imo. | someuwin | |
29/3/2019 15:14 | Wow! Losses rapidly diminishing! Just need another couple of quid a share and I’ll be a happy happy! | yachtmaster2 | |
29/3/2019 14:12 | Maybe next year :) | supernumerary | |
29/3/2019 13:41 | i would like to be | volsung | |
29/3/2019 13:33 | I always thought you were the real volsung :( | supernumerary | |
29/3/2019 12:41 | Through 100p like a hot knife through butter. No resistance until circa 160p. I'm still losing money but it's great to watch getting some of it back. | dickbush | |
29/3/2019 12:15 | #ReNeuron #RENE - trading at £1. A potential six bagger or nine bagger according to these brokers... | someuwin |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions